JP2026500710A - 二重特異性タンパク質を製造する方法 - Google Patents

二重特異性タンパク質を製造する方法

Info

Publication number
JP2026500710A
JP2026500710A JP2025537912A JP2025537912A JP2026500710A JP 2026500710 A JP2026500710 A JP 2026500710A JP 2025537912 A JP2025537912 A JP 2025537912A JP 2025537912 A JP2025537912 A JP 2025537912A JP 2026500710 A JP2026500710 A JP 2026500710A
Authority
JP
Japan
Prior art keywords
protein
antibody
heterodimeric
domain
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025537912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026500710A5 (enExample
Inventor
クライフ，コルネリス アドリアーン デ
モルテンセン，フランツィスカ
Original Assignee
メルス ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2026500710A publication Critical patent/JP2026500710A/ja
Publication of JP2026500710A5 publication Critical patent/JP2026500710A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2025537912A 2022-12-27 2023-12-22 二重特異性タンパク質を製造する方法 Pending JP2026500710A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2033843 2022-12-27
NL2033843 2022-12-27
PCT/NL2023/050681 WO2024144396A1 (en) 2022-12-27 2023-12-22 Method for generating bispecific proteins

Publications (2)

Publication Number Publication Date
JP2026500710A true JP2026500710A (ja) 2026-01-08
JP2026500710A5 JP2026500710A5 (enExample) 2026-03-12

Family

ID=85158672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025537912A Pending JP2026500710A (ja) 2022-12-27 2023-12-22 二重特異性タンパク質を製造する方法

Country Status (8)

Country Link
EP (1) EP4642811A1 (enExample)
JP (1) JP2026500710A (enExample)
KR (1) KR20250129720A (enExample)
CN (2) CN120641444A (enExample)
AU (1) AU2023418349A1 (enExample)
IL (1) IL321671A (enExample)
TW (1) TW202432587A (enExample)
WO (1) WO2024144396A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
KR20230013030A (ko) 2020-05-21 2023-01-26 메뤼스 엔.페. Ig-유사 분자의 생산을 위한 방법 및 수단

Also Published As

Publication number Publication date
CN121824747A (zh) 2026-04-10
AU2023418349A1 (en) 2025-07-03
KR20250129720A (ko) 2025-08-29
IL321671A (en) 2025-08-01
TW202432587A (zh) 2024-08-16
EP4642811A1 (en) 2025-11-05
WO2024144396A1 (en) 2024-07-04
CN120641444A (zh) 2025-09-12

Similar Documents

Publication Publication Date Title
JP7373650B2 (ja) 抗ｐｄ－ｌ１シングルドメイン抗体
JP5681482B2 (ja) 二重特異性抗体およびその作製方法
CN110256569B (zh) 具有交换结合区取向的双重可变区抗体样结合蛋白
CN110913904A (zh) 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
JP6506024B2 (ja) 抗体又は抗体組成物の製造方法
CN110382537B (zh) 抗体结构域的优选配对
JP2024177499A (ja) 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
JP2025063025A (ja) Ｉｇ様分子の製造のための方法および手段
CN114786730A (zh) N-端scFv多特异性结合分子
JP2022546002A (ja) ４価の対称型二重特異性抗体
TWI870360B (zh) 雙特異性抗體構建體之下游加工
JP2025506341A5 (enExample)
KR20250129720A (ko) 이중특이적 단백질을 생성하는 방법
EP4519309A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
CA3205010A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
TW202321312A (zh) 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
US20250019438A1 (en) Optimized CD3 Antigen Binding Domains
JP2025528101A (ja) 多重特異性ポリペプチド複合体
WO2024191322A1 (en) Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof
WO2025162458A1 (zh) 融合抗体及其制备和应用
CN116783218A (zh) 具有降低的免疫原性的抗体可变结构域和抗体
HK40125045A (zh) 承载有效载荷的多特异性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260304